Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers

NCT01929226 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

280

Enrollment

OTHER

Sponsor class

Conditions

Inhalational Anthrax

Interventions

BIOLOGICAL: ETI-204
OTHER: Placebo

Sponsor

Elusys Therapeutics